ChiCTR2500115488 版本V1.0 版本创建时间2025/12/26 15:14:45 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500115488 

最近更新日期:

Date of Last Refreshed on:

2025-12-26 15:14:36 

注册时间:

Date of Registration:

2025-12-26 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

中青年肾癌患者行肾部分切除术癌症复发恐惧现状及相关因素分析

Public title:

Analysis of Fear of Cancer Recurrence and Related Factors in Young and Middle-Aged Patients Undergoing Partial Nephrectomy for Renal Cell Carcinoma

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中青年肾癌患者行肾部分切除术癌症复发恐惧现状及相关因素分析

Scientific title:

Analysis of Fear of Cancer Recurrence and Related Factors in Young and Middle-Aged Patients Undergoing Partial Nephrectomy for Renal Cell Carcinoma

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

罗洁 

研究负责人:

罗洁 

Applicant:

Luo Jie 

Study leader:

Luo Jie 

申请注册联系人电话:

Applicant telephone:

+86 18858181981

研究负责人电话:

Study leader's telephone:

+86 18858181981

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

342172410@qq.com

研究负责人电子邮件:

Study leader's E-mail:

342172410@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市庆春路79号

研究负责人通讯地址:

浙江省杭州市庆春路79号

Applicant address:

No. 79 Qingchun Road, Hangzhou, Zhejiang Province

Study leader's address:

No. 79 Qingchun Road, Hangzhou, Zhejiang Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江大学医学院附属第一医院

Applicant's institution:

The First Affiliated Hospital,Zhejiang University School of Medicine

研究负责人所在单位:

浙江大学医学院附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital,Zhejiang University School of Medicine

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

浙大一院伦审2023研第0918号-快

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

浙江大学医学院附属第一医院IIT伦理审查委员会

Name of the ethic committee:

Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2023-11-20 00:00:00

伦理委员会联系人:

吕朵

Contact Name of the ethic committee:

Lv Duo

伦理委员会联系地址:

浙江省杭州市庆春路79号

Contact Address of the ethic committee:

No. 79 Qingchun Road, Hangzhou, Zhejiang Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 571 87236596

伦理委员会联系人邮箱:

Contact email of the ethic committee:

lvduo8905@foxmail.com

研究实施负责(组长)单位:

浙江大学医学院附属第一医院

Primary sponsor:

The First Affiliated Hospital,Zhejiang University School of Medicine

研究实施负责(组长)单位地址:

浙江省杭州市庆春路79号

Primary sponsor's address:

No. 79 Qingchun Road, Hangzhou, Zhejiang Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江大学医学院附属第一医院

具体地址:

浙江省杭州市庆春路79号

Institution
hospital:

The First Affiliated Hospital,Zhejiang University School of Medicine

Address:

No. 79 Qingchun Road, Hangzhou, Zhejiang Province

经费或物资来源:

中青年肾癌患者行肾部分切除术癌症复发恐惧现状及相关因素分析

Source(s) of funding:

Analysis of Fear of Cancer Recurrence and Related Factors in Young and Middle-Aged Patients Undergoi

Target disease:

Fear of cancer recurrence

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

为探究缓解肾癌肾部切术后患者癌症复发恐惧心理的方法提供参考  

Objectives of Study:

To provide a reference for exploring methods to alleviate the fear of cancer recurrence in patients after renal cancer surgery

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄大于等于18岁且小于等于60岁; 2.符合临床肾细胞癌诊断标准并确诊的患者:根据中国泌尿外科诊断指南,经肾癌专科医生明确诊断者,且进行了肾部分切除术式; 3.腹腔镜或开放的肾部分切除手术且病情稳定的患者; 4.患者无明显认知及语言功能障碍,能独立完成或在照顾者帮助下完成研究所需的问卷调查; 5.对研究内容、研究目的知情同意,自愿参加研究并签署知情同意书。

Inclusion criteria

1.Age is between 18 years and 60 years (inclusive); 2.Patients who met the clinical diagnostic criteria for renal cell carcinoma and were confirmed: According to the Chinese guidelines for urological diagnosis, those diagnosed by a specialized urological oncologist and who underwent partial nephrectomy; 3.Patients who have undergone partial nephrectomy through laparoscopic or open surgery and whose conditions are stable; 4.The patient has no obvious cognitive or language impairments and is able to independently complete or complete the questionnaire survey required for the study with the help of a caregiver; 5.Gives informed consent regarding the research content and purpose, voluntarily participates in the research and signs the informed consent form.

排除标准:

1.因肾癌再次入院治疗者; 2.无法采用语言、文字进行沟通的患者; 3.同期进行了其他手术的患者; 4.合并其他器官、系统原发性恶性肿瘤患者; 5.合并严重的精神疾病或认知功能障碍; 6.中途退出者。

Exclusion criteria:

1.Patients who have been readmitted for treatment due to kidney cancer; 2.Patients who are unable to communicate through language or writing; 3.Patients who underwent other surgeries at the same time; 4.Patients with primary malignant tumors in other organs or systems; 5.Combine severe mental illness or cognitive dysfunction; 6.Those who quit halfway.

研究实施时间:

Study execute time:

From 2024-01-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-07-06 00:00:00 To 2025-07-01 00:00:00  

干预措施:

Interventions:

组别:

观察组

样本量:

231

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江省 

市(区县):

 

Country:

China 

Province:

Zhejiang 

City:

 

单位(医院):

浙江大学医学院附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital,Zhejiang University School of Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

癌症复发恐惧

指标类型:

主要指标

Outcome:

Fear of cancer recurrence

Type:

Primary indicator

测量时间点:

术后5天-术后3个月

测量方法:

Measure time point of outcome:

5 days - 3 months after surgery

Measure method:

指标中文名:

疾病感知

指标类型:

次要指标

Outcome:

Illness Perception

Type:

Secondary indicator

测量时间点:

术后5天-术后3个月

测量方法:

中文版疾病感知问卷简化版(BIPQ)

Measure time point of outcome:

5 days - 3 months after surgery

Measure method:

The Brief Illness Perception Questionnaire (BIPQ)

指标中文名:

健康素养

指标类型:

次要指标

Outcome:

Health Literacy

Type:

Secondary indicator

测量时间点:

术后5天-术后3个月

测量方法:

慢性病病人健康素养量表(HeLMS)

Measure time point of outcome:

5 days - 3 months after surgery

Measure method:

Health Literacy Scale (HeLMS)

指标中文名:

人口学临床特征

指标类型:

次要指标

Outcome:

Demographic clinical characteristics

Type:

Secondary indicator

测量时间点:

术后5天-术后3个月

测量方法:

Measure time point of outcome:

5 days - 3 months after surgery

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

本研究的数据将提交至我国的国家人口健康科学数据中心https://www.ncmi.cn/index.html。在主要研究结果论文发表后 6 个月内开放共享,共享期限至少为 5 年。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The data of this study will be submitted to the National Population Health Science Data Center of our country. It will be made available for sharing within six months after the publication of the main research results paper, and the sharing period will last for at least five years.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

利用EXCEL表格将收集的数据录入保存,双人核对,用于统计分析

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The collected data were entered and saved in an EXCEL table for statistical analysis.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-12-26 15:14:36